CXCR3 and graft versus host disease: They demonstrated in fully-MHC mismatched murine allo-HSCT models that treatment with ruxolitinib led to reduced aGVHD through reduced expression of CXCR3 and less trafficking of donor T cells to GVHD target organs (74).